{"id":26121,"date":"2026-03-17T10:38:39","date_gmt":"2026-03-17T14:38:39","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=26121"},"modified":"2026-03-17T10:38:39","modified_gmt":"2026-03-17T14:38:39","slug":"emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/tr\/emilys-entourage-appoints-david-a-waltz-md-as-first-chief-medical-officer\/","title":{"rendered":"Emily\u2019s Entourage, \u0130lk T\u0131bbi Direkt\u00f6r\u00fc Olarak Dr. David A. Waltz'u Atad\u0131"},"content":{"rendered":"

Kistik fibrozis alan\u0131nda deneyimli bir hekim ve bilim insan\u0131 olan, ayn\u0131 zamanda Vertex Pharmaceuticals\u2019\u0131n eski \u00fcst d\u00fczey y\u00f6neticisi, kistik fibrozis hastalar\u0131n\u0131n son 10%\u2019si i\u00e7in tedavilerin h\u0131zland\u0131r\u0131lmas\u0131na katk\u0131da bulunacak<\/span><\/i><\/p>\n

\"\"Philadelphia, PA\u201417 Mart 2026<\/b>-<\/span>Emily\u2019s Entourage (EE), mevcut CFTR mod\u00fclat\u00f6r tedavilerinden fayda g\u00f6remeyen kistik fibroz (CF) hastalar\u0131n\u0131n son %\u2019si i\u00e7in yeni tedavileri ve bir \u00e7areyi h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)(3) kurulu\u015fudur<\/span>, bug\u00fcn, Dr. David A. Waltz'\u0131n kurulu\u015fun ilk T\u0131bbi Direkt\u00f6r\u00fc (CMO) olarak atand\u0131\u011f\u0131n\u0131 duyurdu.<\/span><\/p>\n

EE\u2019nin b\u00fcy\u00fcmesini ve KF (kistik fibrozis) tedavi geli\u015ftirmeye y\u00f6nelik artan yat\u0131r\u0131m\u0131n\u0131 yans\u0131tan \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olan bu a\u00e7\u0131l\u0131\u015f niteli\u011findeki g\u00f6revde Dr. Waltz; EE\u2019nin ara\u015ft\u0131rma ve tedavi geli\u015ftirme stratejisini g\u00fc\u00e7lendirmek ve kurulu\u015f taraf\u0131ndan finanse edilen umut verici ke\u015fifleri erken a\u015fama bilimsel i\u00e7g\u00f6r\u00fcden klinik geli\u015ftirmeye do\u011fru ilerletmeye yard\u0131mc\u0131 olmak, b\u00f6ylece EE\u2019yi \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerin bir sonraki d\u00f6nemi i\u00e7in konumland\u0131rmak amac\u0131yla Bilimsel Ba\u015f M\u0131zman (CSO) Dr. Chandra Ghose ile yak\u0131n bir \u015fekilde \u00e7al\u0131\u015facakt\u0131r.<\/span><\/p>\n

Biyoteknoloji ve ila\u00e7 sekt\u00f6rlerinde akademik t\u0131p, translasyonel bilim ve klinik ara\u015ft\u0131rma alanlar\u0131nda kariyerine devam eden bir sekt\u00f6r lideri olan Dr. Waltz, son olarak Vertex Pharmaceuticals Inc.'de Ba\u015fkan Yard\u0131mc\u0131s\u0131 ve Kistik Fibrozis Klinik Geli\u015ftirme Ba\u015fkan\u0131 olarak g\u00f6rev yapm\u0131\u015f ve burada, kistik fibrozis (CF) hastalar\u0131n\u0131n yakla\u015f\u0131k %'sinin tedavi s\u00fcrecini yeniden \u015fekillendiren kombinasyon tedavileri de dahil olmak \u00fczere, d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc CFTR mod\u00fclat\u00f6rlerinin geli\u015ftirilmesine \u00f6nc\u00fcl\u00fck etmi\u015ftir.<\/span><\/p>\n

\u201cEmily's Entourage ara\u015ft\u0131rma portf\u00f6y\u00fcm\u00fcz\u00fc geni\u015fletmeye ve yeni nesil tedavilere do\u011fru ilerlemeye devam ederken, ilk Ba\u015f T\u0131bbi Sorumlumuzu g\u00f6reve getirmek misyonumuz i\u00e7in ileriye do\u011fru at\u0131lm\u0131\u015f devasa bir ad\u0131md\u0131r\u201d dedi EE'nin Kurucu Orta\u011f\u0131 MBE Emily Kramer-Golinkoff.\u00a0<\/span><\/p>\n

\u201cMevcut CFTR mod\u00fclat\u00f6r tedavilerinden fayda g\u00f6remeyen CF toplulu\u011fundaki son 10% hastalar\u0131 i\u00e7in zaman \u00e7ok \u00f6nemlidir. Dr. Waltz, bilimsel ke\u015fifleri hayat kurtaran ila\u00e7lara d\u00f6n\u00fc\u015ft\u00fcrme konusunda ola\u011fan\u00fcst\u00fc bir deneyime sahiptir. Onun liderli\u011fi, umut vaat eden tedavilerin h\u0131zla klinik a\u015famaya ta\u015f\u0131nmas\u0131na yard\u0131mc\u0131 olacakt\u0131r.\u201d\u00a0\u00a0<\/span><\/p>\n

Dr. Waltz kariyerine Boston \u00c7ocuk Hastanesi ve Harvard T\u0131p Fak\u00fcltesi'nde kistik fibrozis hastalar\u0131n\u0131 tedavi etti\u011fi ve klinik ara\u015ft\u0131rma giri\u015fimlerine liderlik etti\u011fi pediatrik g\u00f6\u011f\u00fcs hastal\u0131klar\u0131 uzman\u0131 ve hekim-bilim insan\u0131 olarak ba\u015flad\u0131. Daha sonra Novartis Biyomedikal Ara\u015ft\u0131rma Enstit\u00fcleri ve Vertex Pharmaceuticals'da end\u00fcstri liderli\u011fi pozisyonlar\u0131na ge\u00e7i\u015f yaparak, klinik geli\u015fim ve d\u00fczenleyici onay s\u00fcre\u00e7lerinde birden fazla kistik fibrozis tedavisini ilerletmede merkezi bir rol oynam\u0131\u015ft\u0131r.<\/span><\/p>\n

EE\u2019de, \u00f6zellikle translasyonel t\u0131p alan\u0131na odaklanarak kurulu\u015fun artan ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131na y\u00f6n vermeye yard\u0131mc\u0131 olacak; b\u00f6ylece umut vaat eden ke\u015fiflerin laboratuvardan klinik denemelere ve nihayetinde CF hastalar\u0131na verimli bir \u015fekilde aktar\u0131lmas\u0131n\u0131 sa\u011flayacak.<\/span><\/p>\n

\u201cEmily\u2019s Entourage, uzun s\u00fcredir g\u00f6z ard\u0131 edilen topluluk \u00fcyeleri i\u00e7in anlaml\u0131 bir ilerleme kaydetmeye odaklanan amans\u0131z bir yakla\u015f\u0131mla, yenilik\u00e7i KF ara\u015ft\u0131rmalar\u0131 i\u00e7in ola\u011fan\u00fcst\u00fc bir mekanizma yaratt\u0131\u201d dedi Dr. Waltz. \u201cBu misyona kat\u0131lmaktan ve \u00e7\u0131\u011f\u0131r a\u00e7an bilimin, h\u00e2lihaz\u0131rda bekleyen bireylerin ve ailelerin ya\u015famlar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrme g\u00fcc\u00fcne sahip terapilere d\u00f6n\u00fc\u015f\u00fcm\u00fcn\u00fc h\u0131zland\u0131rmaya yard\u0131mc\u0131 olmaktan onur duyuyorum.\u201d<\/span><\/p>\n

Dr. Waltz, ara\u015ft\u0131rma ve klinik geli\u015ftirme stratejisi konusunda dan\u0131\u015fmanl\u0131k yapmas\u0131n\u0131n yan\u0131 s\u0131ra EE i\u00e7in d\u0131\u015fa d\u00f6n\u00fck kilit bir bilimsel lider olarak g\u00f6rev yapacak; akademi, end\u00fcstri ve daha geni\u015f KBH (kistik fibrozis) toplulu\u011fu genelindeki i\u015f birliklerini g\u00fc\u00e7lendirecektir. EE'yi bilimsel forumlarda temsil edecek ve EE'nin ara\u015ft\u0131rma portf\u00f6y\u00fcnden ortaya \u00e7\u0131kan yeni tedavi f\u0131rsatlar\u0131n\u0131 belirlemeye ve ilerletmeye yard\u0131mc\u0131 olmak i\u00e7in klinik ve d\u00fczenleyici uzmanl\u0131\u011f\u0131n\u0131 uygulayacakt\u0131r.<\/span><\/p>\n

Emily'nin \u00c7evresi Hakk\u0131nda<\/b><\/p>\n

Emily's Entourage, mevcut mutasyon hedefli tedavilerden yararlanamayan kistik fibrozis (KF) pop\u00fclasyonunun son 10%'sindeki bireyler i\u00e7in yeni tedaviler ve bir tedavi i\u00e7in ara\u015ft\u0131rmalar\u0131 h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)3't\u00fcr. Emily's Entourage 2011 y\u0131l\u0131ndan bu yana milyonlarca dolarl\u0131k ara\u015ft\u0131rma hibesi vermi\u015f, klinik a\u015famada bir KF gen terapisi \u015firketi kurmu\u015f, klinik deneylere kat\u0131l\u0131m\u0131 h\u0131zland\u0131rmak i\u00e7in k\u00fcresel bir hasta veri taban\u0131 ve klinik deney e\u015fle\u015ftirme program\u0131 geli\u015ftirmi\u015f ve d\u00fcnya \u00e7ap\u0131nda y\u00fcksek etkili ara\u015ft\u0131rma ve ila\u00e7 geli\u015ftirme \u00e7abalar\u0131na \u00f6nc\u00fcl\u00fck etmi\u015ftir. Kurulu\u015f, New York Times, STAT, CNN, People ve daha fazlas\u0131 dahil olmak \u00fczere ulusal medyada yer alm\u0131\u015ft\u0131r. Daha fazla bilgi i\u00e7in <\/span>emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Medya \u0130leti\u015fim<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Pazarlama ve \u0130leti\u015fim Direkt\u00f6r\u00fc<\/span><\/p>\n

hannah@emilysentourage.org<\/span><\/p>\n

###<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Veteran cystic fibrosis physician-scientist and former Vertex Pharmaceuticals senior leader to help accelerate therapies for the final 10% of people with cystic fibrosis Philadelphia, PA\u2014March 17, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating new treatments and a cure for the final 10% of people with cystic fibrosis (CF) that do not benefit from existing… <\/p>\n

<\/div>\n

Daha fazla bilgi edinin<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"none","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[197,217,265,7,267,266],"class_list":["post-26121","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-chief-medical-officer","tag-cystic-fibrosis","tag-ee-cmo","tag-ee-staff"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/26121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/comments?post=26121"}],"version-history":[{"count":2,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/26121\/revisions"}],"predecessor-version":[{"id":26125,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/26121\/revisions\/26125"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media?parent=26121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/categories?post=26121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/tags?post=26121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}